BioXcel posts Q4 net loss $12.5M, IGALMI revenue falls; sNDA filed for at-home use

BioXcel Therapeutics, Inc.

Q4 2025 IGALMI revenue $256K vs $366K in Q4 2024; full year $642K vs $2.3M.
Net loss Q4 $12.5M ($10.9M Q4 2024); full year $69.9M ($59.6M 2024).
Cash $28.8M at Dec 31, 2025; operating cash use $57.6M in 2025 vs $72M in 2024.
sNDA submitted Jan 2026 for IGALMI in at-home agitation; potential approval year-end 2026.
Appointed Mark Pavao as Interim CCO to lead launch plans for IGALMI at-home.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BioXcel Therapeutics, Inc. reported financial results for for the three months and year ended December 31, 2025.

Period: for the three months and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 27, 2026, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2025 and provided a business update.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-035661

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.